Investigation of a first-in-class FRIZZLED4/LRP5 agonist in retinal disease models

Active Project Grant Awarded Last action

Award ID
R01EY033316
Recipient
Awarding agency
Obligated
$7,249,195

Award facts

Assistance listing
93.867 Vision Research
Completion date 97% complete
Funding
  • $6,373,546.00 Federal
  • $875,649.00 Non-federal
Place of performance
Minneapolis, MN 55455, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The blood-retina barrier (BRB) protects the retina by limiting extravasation of solutes and immune cells and by providing active transport mechanisms for required nutrients and hormones. BRB dysfunction is implicated in retinal diseases including diabetic retinopathy, choroidal neovascularization, retinal occlusive diseases, uveitis, macular telangiectasia, familial exudative vitreoretinopathy, retinopathy of prematurity, and coat's disease. Although the key role of canonical norrin and WNT7A/B signaling in inducing and maintaining blood-CNS barriers has been identified, highly potent and therapeutically amenable agonists of these pathways that could promote or restore BRB function are lacking. Signal initiation by norrin requires the receptor FRIZZLED4 (FZD4) and two CO-receptors, low-density-lipoprotein receptor-related protein 5 (LRP5) and tetraspanin-12 (TSPAN12). Here, we use an entirely novel agonist to activate canonical (i.e., beta-catenin-dependent) signaling in endothelial cells. The agonist is a human antibody modality that functionally mimics norrin and WNT7A/B. The mechanism of action and its efficacy in distinct types of BRB defects are not known. We will conduct cell-based experiments to test the hypothesis that the agonist activates signaling by inducing complex formation of receptor and CO-receptor molecules. To understand which types of BRB defects can be restored by the agonist, we will use multiple mouse models with BRB defects that have distinct characteristics. We will determine the efficacy in restoring the BRB in each model, perform transcriptomic experiments and immuno- histochemical analyses to identify mechanism of BRB restoration, and quantify vascular density. BRB defects, e.g., in macular edema, are treated with anti-vegf or anti-inflammatory drugs. However, anti-vegf therapies are not effective in all patients, and other patients may develop resistance. The novel agonist used here has an entirely different pharmacodynamic profile compared to anti-vegf and anti-inflammatory drugs. Therefore, IT is important to evaluate this drug candidate for its therapeutic potential.

Transactions

Action Federal Non-federal Date
Amendment $453,631 $0
Amendment $453,631 $0
Amendment $453,631 $0
Amendment $36,094 $0
Amendment $36,094 $0
Amendment $453,631 $0
Amendment $453,631 $0
Amendment $453,631 $0
Amendment $45,363 $0
Amendment $45,363 $0
Amendment $45,363 $0
Amendment $408,268 $0
Amendment $408,268 $408,268
Amendment $408,268 $0
Amendment $408,268 $0
Amendment $408,268 $0
Amendment $467,381 $0
Amendment $467,381 $467,381
Original award $467,381 $0
Show all 19

Subawards

Subrecipient Amount Awarded
The Governing Council Of The University Of Toronto Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models $423,142
The Governing Council Of The University Of Toronto $328,860

Quick answers

Who received award R01EY033316?

R01EY033316 was awarded to Regents Of The University Of Minnesota by National Eye Institute (National Institutes of Health) on January 1, 2022.

How much is award R01EY033316 worth?

$7,249,195 has been obligated on R01EY033316: $6,373,546 in federal funding and $875,649 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login